Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
The Trump administration has established new Medicaid drug pricing agreements with nine midsize pharmaceutical and biotechnology firms. These deals ensure that every included drug is provided at the lowest available prices. Participating companies include Sun Pharmaceutical Industries Ltd, Bridgebio Pharma Inc, and UCB SA. This latest set of agreements expands on a previous initiative started last year that secured pricing deals with 17 of the world's largest drugmakers, such as Amgen, Eli Lilly, and Pfizer.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The Trump administration announced new Medicaid drug pricing agreements with nine pharmaceutical and biotechnology companies.
- ✓ Participating firms include UCB SA, Bridgebio Pharma Inc, and Sun Pharmaceutical Industries Ltd.
- ✓ The administration previously struck agreements with 17 of the world's largest drugmakers, including Pfizer, Eli Lilly, and Amgen.
- ✓ Every drug under the new deals will be at the lowest prices available anywhere.
What changed
The administration transitioned from planning to announcing finalized pricing deals with nine specific biotech and pharmaceutical firms.
Live updates
-
Trump Announces Medicaid Drug Pricing Deals With Nine Pharma Companies
The Trump administration has established new Medicaid drug pricing agreements with nine midsize pharmaceutical and biotechnology firms. These deals ensure that every included drug is provided at the lowest available prices. Participating companies include Sun Pharmaceutical Industries Ltd, Bridgebio Pharma Inc, and UCB SA. This latest set of agreements expands on a previous initiative started last year that secured pricing deals with 17 of the world's largest drugmakers, such as Amgen, Eli Lilly, and Pfizer.
Why it matters
These agreements target the cost of prescription medications within the Medicaid program. By securing lower prices from midsize manufacturers, the administration aims to reduce government spending and lower costs for beneficiaries. The strategy follows a pattern of negotiating directly with industry players rather than relying solely on legislative mandates.
What is confirmed
- The Trump administration announced new Medicaid drug pricing agreements with nine pharmaceutical and biotechnology companies.
- Participating firms include UCB SA, Bridgebio Pharma Inc, and Sun Pharmaceutical Industries Ltd.
- The administration previously struck agreements with 17 of the world's largest drugmakers, including Pfizer, Eli Lilly, and Amgen.
- Every drug under the new deals will be at the lowest prices available anywhere.
What to watch next
- Publication of the full list of nine pharmaceutical companies involved
- Details on the specific drugs covered by these pricing agreements
confidence 100%Sources used for this update (10)
- CNBC — Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
- MS NOW — White House to announce nearly a dozen new drug pricing deals with pharmaceutical companies
- Reuters — White House to announce new drug pricing deals with biotechs, Bloomberg News reports
- Reuters — Trump administration to announce drug pricing deals
- Bloomberg.com — White House to Announce New Drug Pricing Deals With Biotechs
- WBFF — Trump expected to share new slate of drug pricing deals during healthcare announcement
- www.nbcnews.com — Trump announces new drug-pricing deals with 9 pharma companies
- www.yahoo.com — Trump announces Medicaid drug pricing deals with 9 firms
- www.usatoday.com — Trump touts drug-pricing pacts with these 9 pharma manufacturers
- finance.yahoo.com — Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community